Content

Welcome to the CJU website » LOG IN

Details

Young age is associated with decreased recurrence for renal cell carcinoma
Saint Louis University School of Medicine, St Louis, Missouri, USA
Jun  2022 (Vol.  29, Issue  3, Pages( 11142 - 11149)
PMID: 35691035

Abstract

Text-Size + 

  • Introduction:

    We aimed to examine stage-specific oncologic outcomes for young versus conventional-age patients with localized disease in a modern cohort.

    Materials and methods:

    The Surveillance, Epidemiology and End Results database was queried for patients with T1-T2N0M0 kidney cancer from 1975-2016, including clear cell, papillary, and chromophobe renal cell carcinoma. Patients were stratified into ≤ 40 years-old or > 40 years-old cohorts and underwent definitive treatment via percutaneous ablation, partial nephrectomy, or radical nephrectomy. Primary outcome was cancer-specific survival. Cox regression and Kaplan-Meier analysis were performed.

    Results:

    A total of 44,673 patients were identified with 41,812 patients in the conventional-age and 2,861 patients in the young cohort with mean ages of 62.1 and 34.7 years old, respectively. The young cohort had a higher proportion of T1a disease compared to the conventional-age cohort (65.2% vs. 58.6%) and a lower proportion of the cT1b (24.4% vs. 29.3%), cT2a (6.8% vs. 8.4%), and cT2b (3.6% vs. 3.7%) disease. Chromophobe histology was more prevalent in the younger population (10.5% vs. 6.6%). Nuclear grade 3 or 4 were more prominent in the conventional-age population (24.8% vs. 19.1%). Cancer-specific death was significantly higher in the conventional-age cohort (2.4% vs. 0.7%). Cox regression analysis demonstrated patients > 40 years old, increasing stage, and higher grade were at independently increased risk of cancer-specific death. Kaplan-Meier analysis showed significantly improved 5-year cancer-specific survival for the young versus conventional-age cohorts when sub-stratified by stage.

    Conclusion:

    When stratified by stage, young patients with localized kidney cancer experience improved cancer-specific survival.